Charles B Nemeroff MD PhD
Geriatric Psychiatry, Psychopharmacology, Psychosomatic Medicine
Professor and Chair, Department of Psychiatry, University of Texas at Austin, Dell Medical School and Director, Institute for Early Life Adversity Research
Join to view full profile
1601 Trinity StAustin, TX 78712
Phone+1 512-495-5728
Fax+1 512-495-5482
Dr. Nemeroff is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Charles Nemeroff, MD, is a psychiatrist based in Austin, TX, with subspecialties in geriatric psychiatry, psychopharmacology, and psychosomatic medicine. He completed his medical education at the University of North Carolina at Chapel Hill School of Medicine in 1981, followed by psychiatry residencies at the University of North Carolina Hospitals and Duke University Hospital. Dr. Nemeroff has expertise in treating conditions such as Tourette syndrome, autism spectrum disorders, bipolar disorders, depressive disorders, and suicidal ideation. He has published research on related topics in notable journals, including Neuropsychopharmacology and JAMA Psychiatry. His professional accolades include being elected to the Institute of Medicine and receiving recognition from Consumers' Checkbook and Marquis Who's Who in Medicine and Healthcare.
Education & Training
Duke University HospitalResidency, Psychiatry, 1983 - 1985
University of North Carolina HospitalsResidency, Psychiatry, 1981 - 1983
University of North Carolina at Chapel Hill School of MedicineClass of 1981
Certifications & Licensure
FL State Medical License 2010 - 2027
NC State Medical License 1982 - 2027
GA State Medical License 1991 - 2026
TX State Medical License 2018 - 2026
OK State Medical License 2021 - 2021
American Board of Psychiatry and Neurology Psychiatry- American Board of Psychiatry and Neurology Geriatric Psychiatry
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2002
- Top MD Consumers Checkbook
- Whos Who in Medicine and Healthcare Marquis Whos Who
Publications & Presentations
PubMed
- The effect of cumulative trauma load on suicide risk and thoughts in trauma-exposed youth over two years.Allison Metts, Suzannah K Creech, John Leri, Cody G Dodd, D Jeffrey Newport
Journal of Affective Disorders. 2026-11-15 - Anhedonia in patients with major depressive disorder (MDD): State-of-the-art consensus review.Andrew J Cutler, Anita H Clayton, Andrew D Krystal, Vladimir Maletic, Roger S McIntyre
Psychiatry Research. 2026-10-01 - Enhanced Episodic Memory Encoding Following Modulation of the Amygdala via Transcranial Low-intensity Focused Ultrasound.Manoj K Doss, Sydney R Lambert, Jason Samaha, Sai Prashanth Raja Sundaram, Charles B Nemeroff
Journal of Cognitive Neuroscience. 2026-08-04
Journal Articles
- Screening for Adverse Childhood ExperiencesJeoffry B Gordon, Charles B Nemeroff, JAMA
- American Psychiatric Association PublishingAlik S Widge, Charles B Nemeroff, Ned H Kalin, Thilo Deckersbach, National Institutes of Health
- Response Rate Profiles for Major Depressive Disorder: Characterizing Early Response and Longitudinal NonresponseCharles B Nemeroff, W Edward Craighead, Helen S Mayberg, Boadie W Dunlop, Depression and Anxiety
Lectures
- The Search for Treatments for Veterans with Major DepressionGlobal Technology Community (GTC), Boston, Massachusetts - 9/9/2013
- Side Effects: Adherence, Tolerability And Insight In Psychiatric TreatmentNorth Carolina Psychiatric Association, Asheville, North Carolina - 9/19/2013
- 6th CNS Partnering & Deal-Making Conference 2013Global Technology Community (GTC), Boston, Massachusetts - 9/9/2013
Authored Content
- F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
- F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
Press Mentions
Autoimmune Diseases Tied to Doubling of Mood Disorder RiskJuly 1st, 2025- Max Fink, Champion of Electroconvulsive Therapy, Dies at 102June 27th, 2025
- Seeking Relief from Brain Injury, Some Veterans Turn to PsychedelicsDecember 16th, 2024
Grant Support
- 1/3 Understanding PTSD through Postmortem Targeted Brain Multi-omicsUNIVERSITY OF TEXAS AT AUSTIN2018–2030
- Prediction of Alcohol Use Disorder and PTSD After Trauma in AdolescentsUNIVERSITY OF TEXAS AT AUSTIN2022–2027
- Prediction of Alcohol Use Disorder and PTSD After Trauma in AdolescentsUNIVERSITY OF TEXAS AT AUSTIN2022–2027
- Prospective Determination of Psychobiological Risk Factors for Post-traumatic Stress DisorderNational Institute of Mental Health2012–Present
- Early Life Stress In NON Human Primates And HumansNational Center For Research Resources2005–2009
Professional Memberships
- National Academy of MedicineMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
